

Smart and gentle drug elution

Stents enter the drug eluting era, a major step towards true long-term patency and clinical success. Both depend on good stent performance. As a successful performance starts with a perfect opening, Hemoteq

presents Ouverture® – a high-performance drug-eluting stent platform designed to finally overcome restenosis and thrombosis. Ouverture® combines Hemoteq's proprietary antirestenotic and hemocompatible coatings.

Ouverture®

Repulsion® and Camouflage®

Repulsion® antirestenotic coating

Efficient suppression of restenosis requires potent drugs and an optimized matrix. Hemoteq's versatile drug eluting system has been designed to ensure controlled and safe release for a wide range of drugs. It is biodegradable, biocompatible and hemocompatible.

The smart drug eluting matrix.

Camouflage® hemocompatible coating



Prolonged lesion vulnerability, delayed healing and persistent platelet activation represent significant issues in drug elution. Hemoteq's unique thrombo-protective coating is a covalently bonded synthetic carbohydrate that masks the stent surface as endothelial cells. Biomimicry at its best.

The ultimate gentle surface.

1 Ouverture® dual-layer coating (matrix and basecoat dimensions not to scale).

2 Ouverture® coating on expanded stainless steel stent. Note excellent integrity of the coated surface (blue color for visualization).


Ouverture® can be adapted to virtually any metallic stent material and design. Thanks to excellent elasticity and durability, coated surface integrity is preserved during stent delivery and expansion.



3 Exemplary cytostatic drug in customized DES systems (*)

The Ouverture® platform is adaptable to most hydrophobic, hydrophilic or amphiphilic drugs.

3 Customized elution profiles



Ouverture®

smart and gentle drug elution


4 Drug-free Ouverture® system consisting of a polymer-only biodegradable matrix coating outperforms bare 316L stents in porcine coronary injury model.

After 6 weeks in vivo matrix biodegradation was completed (*).

In vivo performance proves this matrix system an unmatched so far platform for drug elution.

(*) data on file, Hemoteq GmbH

4 Antirestenotic protection



Shaping the future of drug elution

Hemoteq's coating expertise builds on:

- patient oriented approach
- learning from nature – biomimicry
- high quality and safety standards
- permanent innovation

HEMOTEQ AG

Adenauerstrasse 15
52146 Wuerselen
Germany

phone +49(0)24 05.45 50 00

fax +49(0)24 05.45 50 12

e-mail hemoteq@hemoteq.com

www hemoteq.com